Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localized prostate cancer. We sought to assess the aggregate trial-level performance of commonly reported intermediate clinical endpoints.
